×
DMA: Data and Marketing Association
Consumer Help
pharmaceutical-healthcare

Entyvio Launch Campaign

Agency: Pathway / BBDO NY    •    Client: Takeda Pharmaceuticals/Entyvio    •    Category: Pharmaceutical / Healthcare    •    Award: Certificate

ENTYVIO is a prescription biologic infusion drug indicated for patients with moderate to severe ulcerative colitis (UC) and Crohn's Disease (CD). Target Audience: Moderate to severe UC or CD patients whose treatments are failing, specifically 48% (Male) / 52% (Female) aged 25-54. Objectives: Driving awareness and education for ENTYVIO amongst uncontrolled UC and CD patients as a new treatment option that is GI-focused and proven to provide relief and remission

Thank You For Reading

Don't Stop Now. Become A DMA Member!

This content is limited to DMA Members. Become a member to get full access to all of our resources!

Learn More

Already a DMA Member?

×
×
Our Brands EducationEventsAdvocacy MembershipAccountability ResourcesKnowledge CenterAbout UsBlogContact Us

Login To Your Account